An Observational Retrospective Matched Cohort Study of Healthcare Resource Utilisation and Costs in UK Patients with Moderate to Severe Osteoarthritis Pain

被引:3
|
作者
Abraham, Lucy [1 ]
Halsby, Kate [1 ]
Stein, Norman [2 ,3 ]
Wrona, Bozydar [2 ]
Emir, Birol [4 ]
Stevenson, Hannah [1 ]
机构
[1] Pfizer Ltd, Surrey, England
[2] NorthWest EHlth, Manchester, Lancs, England
[3] Univ Manchester, Manchester Acad Hlth Sci Ctr, Manchester, Lancs, England
[4] Pfizer, New York, NY USA
关键词
Analgesia; Arthroplasty; Chronic pain; England; Healthcare cost; Hospitalisation; Length of stay; Osteoarthritis; Primary health care; Regional health planning; KNEE OSTEOARTHRITIS; WORK PRODUCTIVITY; MANAGEMENT; EPIDEMIOLOGY; IMPACT; PHARMACOTHERAPIES; RECOMMENDATIONS; BURDEN; HIP;
D O I
10.1007/s40744-022-00431-2
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Introduction Using data from patients residing in Salford, UK, we aimed to compare healthcare resource utilisation (HCRU) and direct healthcare costs between patients with moderate to severe (M-S) or severe osteoarthritis (OA) pain and those without OA. Methods Patients with a M-S OA pain event within a period of chronic pain were indexed from the Salford Integrated Record (SIR) between 2010 and 2017. Patients with a severe pain event formed an OA subcohort. Patients in each OA pain cohort were independently matched to patients without OA, forming two control cohorts. HCRU, prescribed analgesic drugs, and total direct costs per UK standardised tariffs were calculated for the year post-index. Multivariable models were used to identify drivers of healthcare cost. Results The M-S OA pain and control cohorts each comprised 3123 patients; the severe OA pain and control cohorts each comprised 1922 patients. Patients in both OA pain cohorts had a significantly higher mean number of general practitioner encounters, inpatient, outpatient, and accident and emergency visits, and were prescribed a broader range of analgesic drugs in the year post-index than respective controls. Mean healthcare costs of all types were significantly higher in the M-S and severe OA pain cohorts vs controls (total: M-S 2519 pound vs 1379; pound severe 3389 pound vs 1397) pound. Paracetamol (M-S: 40% of patients had at least one prescription; severe: 50%) and strong opioids (34% and 59%) were the analgesics most prescribed to patients with OA pain. In all cohorts, multivariable models showed that a higher age at index, the presence of gout, osteoporosis, type 2 diabetes, or coronary artery disease, significantly contributed towards higher healthcare costs. Conclusion In the population of Salford, UK, patients with M-S OA pain had significantly higher annual HCRU and costs compared with matched controls without OA; generally, these were even higher in patients with severe OA pain.
引用
收藏
页码:851 / 874
页数:24
相关论文
共 50 条
  • [1] An Observational Retrospective Matched Cohort Study of Healthcare Resource Utilisation and Costs in UK Patients with Moderate to Severe Osteoarthritis Pain
    Lucy Abraham
    Kate Halsby
    Norman Stein
    Bozydar Wrona
    Birol Emir
    Hannah Stevenson
    Rheumatology and Therapy, 2022, 9 : 851 - 874
  • [2] HEALTHCARE RESOURCE UTILISATION AND COSTS AMONG PATIENTS WITH MODERATE TO SEVERE OSTEOARTHRITIS PAIN: A NONINTERVENTIONAL RETROSPECTIVE COHORT STUDY IN SALFORD, UK
    Abraham, L.
    Halsby, K.
    Emir, B.
    Stevenson, H.
    OSTEOPOROSIS INTERNATIONAL, 2021, 32 (SUPPL 1) : S149 - S149
  • [3] Healthcare resource utilisation and costs associated with AL amyloidosis: a retrospective matched cohort study
    Shen, Shih-Pei
    Hou, Hsin-An
    Huang, Kuan-Chih
    Goh, Choo Hua
    Qiu, Hong
    Rothwell, Lee Anne
    Wu, Kwang-Wei
    Chandwani, Hitesh
    Liu, Yanfang
    Tang, Chao-Hsiun
    SCIENTIFIC REPORTS, 2024, 14 (01):
  • [4] HEALTHCARE RESOURCE UTILIZATION AND COSTS ASSOCIATED WITH MODERATE-TO-SEVERE OSTEOARTHRITIS PAIN
    Hansen, R. N.
    Schepman, P. B.
    Robinson, R. L.
    Thakkar, S.
    Beck, C. G.
    Malhotra, D.
    Emir, B.
    OSTEOPOROSIS INTERNATIONAL, 2020, 31 (SUPPL 1) : S565 - S565
  • [5] Healthcare resource utilisation and related costs of patients with CKD from the UK: a report from the DISCOVER CKD retrospective cohort
    Pollock, Carol
    James, Glen
    Garcia Sanchez, Juan Jose
    Carrero, Juan Jesus
    Arnold, Matthew
    Lam, Carolyn S. P.
    Chen, Hungta
    Nolan, Stephen
    Pecoits-Filho, Roberto
    Wheeler, David C.
    CLINICAL KIDNEY JOURNAL, 2022, 15 (11) : 2124 - 2134
  • [6] Healthcare Resource Utilization and Costs Associated with AL Amyloidosis: A Retrospective Matched Cohort Study
    Hou, Hsin-An
    Shen, Shih-Pei
    Huang, Kuan-Chih
    Goh, Choo Hua
    Qiu, Hong
    Rothwell, Lee Anne
    Wu, Kwang-We
    Chandwani, Hitesh
    Liu, Yanfang
    Tang, Chao-Hsiun
    BLOOD, 2022, 140 : 10837 - 10838
  • [7] QUANTIFYING HEALTHCARE RESOURCE UTILISATION FOR THE MANAGEMENT OF MODERATE-TO-SEVERE CHRONIC PAIN AMONG PATIENTS WITH OSTEOARTHRITIS IN ENGLAND: A RETROSPECTIVE ANALYSIS OF LINKED PRIMARY AND SECONDARY CARE DATA
    Lohan, C.
    Stevenson, H.
    Coates, G.
    Wood, R.
    Blackburn, S.
    Tritton, T.
    Knaggs, R.
    Dickson, A. J.
    Walsh, D. A.
    OSTEOARTHRITIS AND CARTILAGE, 2021, 29 : S384 - S384
  • [8] Attendance-related Healthcare Resource Utilisation and Costs in Patients With Brugada Syndrome in Hong Kong: A Retrospective Cohort Study
    Lee, Sharen
    Chung, Cheuk To
    Chou, Oscar Hou In
    Lee, Teddy Tai Loy
    Radford, Danny
    Jeevaratnam, Kamalan
    Wong, Wing Tak
    Cheng, Shuk Han
    Mok, Ngai Shing
    Liu, Tong
    Tse, Gary
    CURRENT PROBLEMS IN CARDIOLOGY, 2023, 48 (02)
  • [9] Excess Healthcare Costs and Resource Utilisation of Lyme Borreliosis in Germany: A Propensity Score-Matched Cohort Study
    Brestrich, Gordon
    Diesing, Joanna
    Kossack, Nils
    Stark, James H.
    Pilz, Andreas
    Yu, Holly
    Suess, Jochen
    ZOONOSES AND PUBLIC HEALTH, 2025, 72 (01) : 23 - 31
  • [10] A UK retrospective observational study of clinical outcomes and healthcare resource utilisation of infliximab treatment in Crohn's disease
    Lindsay, J. O.
    Chipperfield, R.
    Giles, A.
    Wheeler, C.
    Orchard, T.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2013, 38 (01) : 52 - 61